A Changing Focus in the Chinese Pharmaceutical Market?LYON, France -- Reportlinker.com announces that a new market research report related to the Chinese pharmaceutical market is now available to its catalogue. Chinese Pharmaceutical Market Overview - Regulatory reform Regulatory Reform concerns improvements to the quality of government regulation. At the international level, the "OECD Regulatory Reform Programme is aimed at helping governments improve regulatory quality -- that is, reforming regulations that raise unnecessary obstacles to and the evolving healthcare market provide opportunities in china www.reportlinker.com/p044133/chinese-pharmaceutical-market.html Introduction The Chinese pharmaceutical market, although only positioned ninth globally, has experienced pronounced and rapid expansion in recent years, driven by the growth of both Chinese and Western manufacturers. Increasingly, there is a shift towards a research-based industry, focused on generating new, innovative therapies, supported by improving intellectual property regulations. Scope Overview of macro-environmental and regulatory issues affecting the Chinese pharmaceutical industry Assessment of the Chinese pharmaceutical market, analyzing the key prescription therapy areas, as well as OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). and TCM (1) (Trellis-Coded Modulation/Viterbi Decoding) A technique that adds forward error correction to a modulation scheme by adding an additional bit to each baud. TCM is used with QAM modulation, for example. medicines Case study analysis of key Western and Chinese manufacturers in China Insight into the key opportunities for Western manufacturers in China, and the areas likely to provide revenue growth in the future Highlights With improvements in intellectual property regulations, Government funding and the growth of tax incentivized Special Economic Zones, China's R&D environment is developing fast. Western manufacturers are increasingly looking towards China as a place to conduct drug discovery and clinical trial research, although a number of challenges still remain. China is becoming an increasingly competitive environment due to ongoing price competition, and numerous Governmental price cuts. Unless Western manufacturers have Chinese based manufacturing plants which can produce generic drugs generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. at low-cost, there is little financial incentive or future prospects for foreign companies in the generics market. China still exemplifies the disease and treatment profile of a developing market, with a focus on prescribing anti-infectives. However, with westernization west·ern·ize tr.v. west·ern·ized, west·ern·iz·ing, west·ern·iz·es To convert to the customs of Western civilization. west of diet and lifestyle, and China's improving healthcare system, treatment of more chronic disorders will eventually become more of a priority in the future. Reasons to Purchase Understand the dynamics of the Chinese pharmaceutical market and the effect of recent changes to pricing, reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. and patent regulations Identify China's R&D attractions, which are encouraging Western manufacturers to off-shore and out source drug discovery and clinical trials in China Optimize optimize - optimisation your Chinese market growth strategy through detailed knowledge of the performance of the Chinese and Western manufacturers in China. TABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY Scope of the report IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. caveat Insights into the Chinese pharmaceutical market, 2006 China - a place for drug discovery and clinical trial partnerships? A changing focus in the Chinese pharmaceutical market? China - a land of opportunity for Western pharmaceutical manufacturers CHAPTER 2 MACRO-ENVIRONMENTAL ISSUES AFFECTING THE CHINESE PHARMACEUTICAL INDUSTRY Key findings General country information - China A changing economy An overview of China's healthcare system The current scenario Administrative and regulatory bodies of the healthcare system in China SFDA's increased focus on improving drug safety China's health reforms - hope for the future? Healthcare expenditure and funding in China Healthcare expenditure and financing set to improve Health insurance coverage - increasing, but still insufficient CHAPTER 3 REGULATORY ISSUES IN CHINA Key findings Reimbursement is negotiated with local authorities rather than at national level Pharmaceutical Catalog catalog, descriptive list, on cards or in a book, of the contents of a library. Assurbanipal's library at Nineveh was cataloged on shelves of slate. The first known subject catalog was compiled by Callimachus at the Alexandrian Library in the 3d cent. B.C. classification Continuing national price cuts pose significant dilemmas for manufacturers A complex distribution system in China Despite ongoing IP improvements, counterfeiting counterfeiting, manufacturing spurious coins, paper money, or evidences of governmental obligation (e.g., bonds) in the semblance of the true. There must be sufficient resemblance to the genuine article to deceive a person using ordinary caution. provides a significant threat to public health and drug development Implications - China is too risky for the manufacturing of on-patent APIs GMP GMP (guanosine monophosphate): see guanine. - improving but still some way to go before Western manufacturers and regulatory agencies regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. are fully satisfied Drug approvals Priority review procedures - public health crises CHAPTER 4 CHINESE MARKET ASSESSMENT - PERFORMANCE BENCHMARKING Key findings The Chinese pharmaceutical market China compared to the seven major markets Other emerging countries - stressing China's advantages and challenges Which therapy classes are growing? Competitive positioning of the top Chinese pharmaceutical players Traditional Chinese Medicine Traditional Chinese Medicine Definition Traditional Chinese medicine (TCM) is an ancient and still very vital holistic system of health and healing, based on the notion of harmony and balance, and employing the ideas of moderation and prevention. (TCM) - a strong past and bright future Regulation and GMP - the way forward for TCMs Joint ventures are increasingly popular, driving TCM R&D OTC in China set to increase further in the coming decades Bayer acquires OTC cough cough, sudden, forceful expiration of air from the lungs caused by an involuntary contraction of the muscles controlling the process of breathing. The cough is a response to some irritating condition such as inflammation or the presence of mucus (sputum) in the and cold portfolio from Topsun Science and Technology Internet pharmacy internet pharmacy Online A website that offers prescription drugs from the comfort of home Cons The IP or prescribing physician may not be qualified or licensed to prescribe drugs in all states. See Operation Cure-All, VIPPS. is playing an increasing role in the OTC market Noun 1. OTC market - a stock exchange where securities transactions are made via telephone and computer rather than on the floor of an exchange over-the-counter market OTC market entry recommendations CHAPTER 5 CHINESE DOMESTIC PHARMACEUTICAL COMPANY OVERVIEW Key findings Chinese Pharma companies have traditionally driven growth through the API (Application Programming Interface) A language and message format used by an application program to communicate with the operating system or some other control program such as a database management system (DBMS) or communications protocol. and generics business Bulk manufacturing continues to drive China's export industry Overview of China's R&D pipeline Generics and biosimilars There is little incentive for MNCs to enter the generics market Chinese biosimilars players Dragon Pharmaceutical - China's leading biosimilar company CHAPTER 6 OPPORTUNITIES FOR WESTERN MANUFACTURERS IN CHINA China - a land of opportunity for Western pharmaceutical manufacturers China - a place for drug discovery and clinical trial partnerships? China's Key R&D attractions Foreign companies' drug discovery outsourcing (1) Contracting with outside consultants, software houses or service bureaus to perform systems analysis, programming and datacenter operations. Contrast with insourcing. See netsourcing, ASP, SSP and facilities management. activity in China MNCs are increasingly entering clinical trial partnerships for drugs for domestic and worldwide use Key Western players in China - case studies Key differences between AstraZeneca, Novo Nordisk Wikipedia is not the place for advertisement or self-advertising. Novo Nordisk (, NYSE: NVO) manufactures and markets pharmaceutical products and services. Founded in Denmark in 1923, the company has since become a world leader in diabetes care with the broadest and GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) operations in China AstraZeneca - rejuvenated re·ju·ve·nate tr.v. re·ju·ve·nat·ed, re·ju·ve·nat·ing, re·ju·ve·nates 1. To restore to youthful vigor or appearance; make young again. 2. growth in recent years Novo Nordisk - continued high growth rate GSK - flat revenues due to increased generic competition on old drugs CHAPTER 7 CHINESE PHARMACEUTICAL COMPANY PROFILES Previously highly fragmented frag·ment n. 1. A small part broken off or detached. 2. An incomplete or isolated portion; a bit: overheard fragments of their conversation; extant fragments of an old manuscript. 3. and regionalized Leading domestic manufacturers sales in China Yangtze River Yangtze River Chinese Chang Jiang or Ch'ang Chiang River, China. Rising in the Tanggula Mountains in west-central China, it flows southeast before turning northeast and then generally east across south-central and east-central China to the East China Pharmacy pharmacy, art of compounding and dispensing drugs and medication. The term is also applied to an establishment used for such purposes. Until modern times medication was prepared and dispensed by the physician himself. In the 18th cent. Group Overview Strategy Therapy area focus and revenue generation Partners The Harbin Pharmaceutical Group Overview Strategy Therapy area focus and revenue generation HRP in the news Jiangsu Hengrui Medicine Company Overview Strategy Therapy area focus and revenue generation R&D investment and pipeline focus Partners Shandong Qilu Medicines Shanghai Shanghai (shăng`hī`, shäng`hī`), city (1994 est. pop. 12,980,000), in, but independent of, Jiangsu prov., E China, on the Huangpu (Whangpoo) River where it flows into the Chang (Yangtze) estuary. Pharmaceutical Group - Asia Pioneer Shanxi Pude Pharmaceuticals JL Weiwei Pharmaceuticals Guangzhou Tian Tian or T'ien (Chinese; “Heaven”) In indigenous Chinese religion, the supreme power reigning over humans and lesser gods. The term refers to a deity, to impersonal nature, or to both. Xin TH James-Andy Shandong Lunan Better Pharmaceutical Chongqing Yaoyou Pharmaceutical Company Shandong Reyoung Pharmaceutical Company CHAPTER 8 BIBLIOGRAPHY bibliography. The listing of books is of ancient origin. Lists of clay tablets have been found at Nineveh and elsewhere; the library at Alexandria had subject lists of its books. Bibliography Websites Journals and press articles Scrip APPENDIX IMS caveat Exchange rate LIST OF TABLES Table 1: Economic statistics - China, 2005 Table 2: Main economic indicators Economic indicators The key statistics of the economy that reveal the direction the economy is heading in; for example, the unemployment rate and the inflation rate. for seven of the world's largest economies (2003) Table 3: China, country-specific healthcare information of interest, 2005 Table 4: Selected Chinese national health accounts indicators, 2003 Table 5: Ministry level agencies with health authority in China, 2006 Table 6: Distribution of drug products in the 2004 Pharmaceutical Catalog Table 7: Chamber of Commerce's report recommendations, September 2006 Table 8: Prescription pharmaceutical sales per capita [Latin, By the heads or polls.] A term used in the Descent and Distribution of the estate of one who dies without a will. It means to share and share alike according to the number of individuals. across the US, 5EU, Japan and China, 2005 Table 9: Top five ATC ATC Air Traffic Control ATC Average Total Cost ATC Certified Athletic Trainer ATC At the Center (Hartford, Maine retreat center) ATC Applied Technology Council ATC All Things Considered classes by revenue in China, the US and 5EU, 2005 Table 10: Top five ATC classes by volume in China, the US and 5EU, 2005 Table 11: Top domestic and Western pharmaceutical manufacturers in China, 2005 Table 12: Average (mean) sales characteristics of manufacturer groupings, 2004-05 Table 13: Top OTC players in China by value ($m), 2004 Table 14: Dragon Pharmaceutical's biosimilar product portfolio and pipeline, 2006 Table 15: Advantages and disadvantages of clinical trials and R&D in China, 2006 Table 16: Key R&D investments by the top global pharmaceutical companies in China, 2005-06 Table 17: State Governmental scientific support programs Table 18: Key drug discovery outsourcing deals involving Chinese service providers, 2005-2006 Table 19: Mean price comparison between domestically produced and imported products, 2005 Table 20: AstraZeneca's product portfolio in China, 2004-05 Table 21: Novo Nordisk's product portfolio in China, 2004-05 Table 22: GSK's therapy franchises in China, 2004-05 Table 23: GSK's product portfolio in China, 2004-05 Table 24: Leading domestic manufacturers in China ($m), 2004-05 Table 25: Yangtze River Pharmaceutical Group's Chinese revenue breakdown by therapy area, 2004-05 Table 26: Yangtze River Pharmaceutical Group's top 10 products in China, 2004-05 Table 27: Harbin Pharmaceutical Group's Chinese revenue breakdown by therapy area ($m), 2004-05 Table 28: Harbin Pharmaceutical Group's top 10 products in China, 2004-05 Table 29: Harbin Pharmaceutical Group news, 2005-06 Table 30: Jiangsu Hengrui Medicine Company's total Chinese revenue breakdown by therapy area, 2004-05 Table 31: Jiangsu Hengrui Medicine Company's top 10 products in China ($m), 2004-05 Table 32: Jiangsu Hengrui Medicine Company's patent list, 2004-06 Table 33: Shandong Qilu Medicines total Chinese revenue breakdown by therapy area ($m), 2004-05 Table 34: Shanghai Pharmaceutical Group - Asia Pioneer total Chinese revenue breakdown by therapy area ($m), 2004-05 Table 35: Shanxi Pude Pharmaceuticals total Chinese revenue breakdown by therapy area ($m), 2004-05 Table 36: JL Weiwei Pharmaceuticals total Chinese revenue breakdown by therapy area ($m), 2004-05 Table 37: Guangzhou Tian Xin Pharmaceuticals total Chinese revenue breakdown by therapy area ($m), 2004-05 Table 38: TH James-Andy total Chinese revenue breakdown by therapy area ($m), 2004-05 Table 39: Shandong Lunan Better Pharmaceutical total Chinese revenue breakdown by therapy area ($m), 2004-05 Table 40: Chongqing Yaoyou Pharmaceutical Company total Chinese revenue breakdown by therapy area ($m), 2004-05 Table 41: Shandong Reyoung Pharmaceutical Company total Chinese revenue breakdown by therapy area ($m), 2004-05 Table 42: Exchange rates* LIST OF FIGURES Figure 1: Pros and cons pros and cons Noun, pl the advantages and disadvantages of a situation [Latin pro for + con(tra) against] of drug discovery and clinical trials in China Figure 2: Marketed biosimilar products from Chinese manufacturers, 2006 Figure 3: Size and revenue growth by therapy in the Chinese pharmaceutical market, 2001-05 Figure 4: China's major trading partners Figure 5: Total expenditure on health as percentage of GDP GDP (guanosine diphosphate): see guanine. , 2003 Figure 6: Rise in cost of healthcare versus income in China, 1989-2001 Figure 7: Proportion of healthcare expenditure versus GDP, 1978-2004 Figure 8: Drug reimbursement in China, 2005 Figure 9: Branded drug price breakdown in China, 2006 Figure 10: Drug distribution channels in China, 2006 Figure 11: WTO See World Trade Organization. timeline for revamping of China's pharmaceutical distribution networks, 2001-07 Figure 12: Protection of pharmaceutical products in China with or without a patent, 2006 Figure 13: Key steps for drug approval in China, 2006 Figure 14: Comparison of Approvals of New Drug Applications (NDAs) in the US and China, 2004 Figure 15: Comparison of the number of BLA BLA abbr. Bachelor of Liberal Arts and NME NME Name NME Enemy NME New Musical Express NME Neisseria Meningitidis NME New Molecular Entities (US FDA New Drug Approval reports) NME Network Management Ethernet NME New Music Express submissions in the US and China, 2000-04 Figure 16: Manufacturing and distribution in China, 2005 Figure 17: The Chinese pharmaceutical market size in comparison with the seven major markets, 2005 Figure 18: Estimates of China's prescription pharmaceutical market, 2004 Figure 19: Growth of the Chinese pharmaceutical market, 2001-05 Figure 20: Comparison of the Chinese, major seven developed, and emerging pharmaceutical markets, 2001-05 Figure 21: Positioning of emerging countries compared to China, 2006 Figure 22: Distribution of therapy area (ATC class) by revenue in China, the US and EU, 2005 Figure 23: Positioning of therapy classes by revenue from the leading domestic and Western manufacturers in China, 2005 Figure 24: Domestic manufacturers only lead the Western players in anti-infectives, 2006 Figure 25: Distribution of revenues by therapy area (ATC code) for the top 10 domestic and Western manufacturers in China, 2005 Figure 26: Leading domestic manufacturers have outstripped Western players in terms of product launches during 2004-05 Figure 27: Revenue growth of the top 10 leading Western and domestic manufacturers in China, 2001-05 Figure 28: Competitive positioning of top domestic and Western pharmaceutical companies in China, 2005 Figure 29: Competitive positioning of top Western pharmaceutical companies in China and the rest of the world by revenue ($), 2005 Figure 30: Competitive positioning of top pharmaceutical companies in China and the rest of the world by revenue growth (%), 2004-05 Figure 31: Competitive positioning of top pharmaceutical companies in China and the rest of the world by CAGR CAGR See: Compound Annual Growth Rate , 2001-05 Figure 32: Number of new product launches in China by Western manufacturers, 2002-05 Figure 33: Number of new product launches in China by domestic manufacturers, 2002-05 Figure 34: R&D expenditure on Traditional Chinese Medicine, 2002-04 Figure 35: China OTC market value and growth ($), 2000-04 Figure 36: China OTC market by segmentation, 2004 Figure 37: Distribution of OTC medicines in China, 2004 Figure 38: China's pharmaceutical imports versus exports, 2004 Figure 39: Pipeline drug candidates in China by franchise, 2006 Figure 40: Segmentation of the Chinese pharmaceutical market revenues by license status, 2005 Figure 41: Marketed biosimilar products from Chinese manufacturers, 2006 Figure 42: Size and revenue growth by therapy in the Chinese pharmaceutical market, 2001-05 Figure 43: Competitive positioning of top domestic and Western pharmaceutical companies in China, 2005 Figure 44: Revenue growth of AstraZeneca's, GSK's and Novo Nordisk's imported and domestic products, 2001-05 Figure 45: Revenues and growth of AstraZeneca's lead franchises in China, 2001-05 Figure 46: Growth and share of revenues and SUs between AstraZeneca and AZ-Wuxi in China, 2001-05 Figure 47: Novo Nordisk - the largest and one of the fastest growing diabetes franchises in China, 2005 Figure 48: Growth and share of revenues and volume between Novo Nordisk and Novo Nordisk Tianjin in China, 2001-05 Figure 49: Revenues and growth of GSK's lead franchises in China, 2001-05 Figure 50: GSK China - declining revenues and volume, 2001-05 More market research reports? Go to http://www.reportlinker.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion